We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Orbicularis Oculi Weakness and Obstructive Meibomian Gland Disease

Richard C. Allen, MD, PhD1; Ryan J. Wise, MD2
[+] Author Affiliations
1Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, Iowa City
2Department of Ophthalmology, University of Indiana School of Medicine, Indianapolis
JAMA Ophthalmol. 2014;132(12):1490-1491. doi:10.1001/jamaophthalmol.2014.2986.
Text Size: A A A
Published online


To the Editor We read with special interest the article titled “Botulinum Toxin Type A Injection for Lateral Canthal Rhytids: Effect on Tear Film Stability and Tear Production” by Ho et al1 and offer additional support for the mechanism by which botulinum toxin injection may alter the functioning of the meibomian glands that was not referenced by the authors. Ho and colleagues hypothesize that injection of botulinum toxin type A at the lateral canthus may diffuse to the pretarsal orbicularis and affect the emptying of the meibomian glands. As a diffusion radius of 2 to 4 cm would likely involve the pretarsal orbicularis, the authors hypothesize that “[p]aralysis of these muscles by botulinum toxin will decrease the driving force for meibomian oil excretion.”1 This is based on the pathology of the muscle of Riolan, which is a distinct subdivision of striated orbicularis muscle and is hypothesized to compress the meibomian gland ductules, aiding in expression of their contents.2


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...